References of "Bruyère, Olivier"
     in
Bookmark and Share    
Full Text
See detailEffets symptomatiques de la glucosamine dans l’arthrose
Reginster, Jean-Yves ULg; Bruyère, Olivier ULg

in Pharma-Sphère (2006), 110

Detailed reference viewed: 16 (10 ULg)
See detailQualité des travaux de fin d'études
Bruyère, Olivier ULg

Conference (2005, December 06)

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailThree year joint space narrowing predicts long term incidence of knee surgery in patients with osteoarthritis: an eight year prospective follow up study
Bruyère, Olivier ULg; Richy, F.; Reginster, Jean-Yves ULg

in Annals of the Rheumatic Diseases (2005), 64(12), 1727-1730

OBJECTIVE: To assess the clinical relevance of mean and minimum femorotibial joint space narrowing (JSN) for predicting future osteoarthritis related surgery in patients with knee osteoarthritis. METHODS ... [more ▼]

OBJECTIVE: To assess the clinical relevance of mean and minimum femorotibial joint space narrowing (JSN) for predicting future osteoarthritis related surgery in patients with knee osteoarthritis. METHODS: 126 subjects with primary knee osteoarthritis were followed prospectively for a mean eight years. Minimum and mean joint space width (JSW) were assessed from standard x rays at baseline and after a follow up of three years. The rate of knee osteoarthritis related surgery was recorded for the following five years. RESULTS: After a mean follow up of eight years, 16 patients (12.7%) had received osteoarthritis related joint surgery. The areas under the curves (AUC) resulting from the receiver operating characteristic curve analyses for predicting osteoarthritis surgery were 0.73 (p=0.006) for minimum JSN and 0.55 (p=0.54) for mean JSN. The cut off for minimum JSN maximising sensitivity and specificity for predicting future surgery was a change of 0.7 mm or more in minimum joint space width over a period of three years. However, no meaningful differences were observed for cut off values between 0.5 and 0.8 mm The relative risk (adjusted for age, body mass index, baseline symptoms, and baseline JSW) of experiencing osteoarthritis related surgery during the eight year of follow up was 5.15 (95% confidence interval, 1.70 to 15.60) (p=0.004) in patients with a minimum joint space narrowing of 0.7 mm or more during the first three years of the study. CONCLUSIONS: A cut off of 0.5 to 0.8 mm in minimum JSN, measured on standard x rays, reflects a clinically relevant progression in patients with knee osteoarthritis. [less ▲]

Detailed reference viewed: 39 (9 ULg)
Full Text
Peer Reviewed
See detailSelf-reported versus measured prevalence of osteoporosis. An age-stratified analysis of its diagnostic coverage
Richy, Florent; Bruyère, Olivier ULg; Maassen, Philippe et al

in Arthritis and Rheumatism (2005, September), 52(number 9 (suppl.)), 228-229

Detailed reference viewed: 6 (1 ULg)
Full Text
Peer Reviewed
See detailMagnetic Resonance Imaging and biochemical markers of osteoarthritis of the knee
Kothari, Manish; Bruyère, Olivier ULg; COLLETTE, Julien ULg et al

in Arthritis and Rheumatism (2005, September), 52(number 9 (suppl.)), 71

Detailed reference viewed: 8 (2 ULg)
Full Text
Peer Reviewed
See detailLongitudinal study of magnetic resonance imaging and fixed-flexion radiography to assess progression of osteoarthritis of the knee
Kothari, Manish; Peterfy, Charles; Bruyère, Olivier ULg et al

in Arthritis and Rheumatism (2005, September), 52(number 9 (suppl.)), 65

Detailed reference viewed: 8 (0 ULg)
Full Text
Peer Reviewed
See detailStrontium Ranelate (Fujisawa/Servier)
Jupsin, Isabelle ULg; Collette, Julien ULg; Henrotin, Yves ULg et al

in Current Opinion in Investigational Drugs (London, England : 2000) (2005), 6(4), 435-44

Strontium ranelate (PROTELOS), a divalent strontium salt, has been developed and launched by Servier for the treatment of osteoporosis. Fujisawa Pharmaceutical is developing the drug in Japan; in November ... [more ▼]

Strontium ranelate (PROTELOS), a divalent strontium salt, has been developed and launched by Servier for the treatment of osteoporosis. Fujisawa Pharmaceutical is developing the drug in Japan; in November 2004, phase II Japanese trials were ongoing. [less ▲]

Detailed reference viewed: 37 (5 ULg)
Full Text
Peer Reviewed
See detailTotal joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis
Altman, R. D.; Abadie, Eric ULg; Avouac, B. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 10

Detailed reference viewed: 34 (2 ULg)
Full Text
Peer Reviewed
See detailScreening for osteoporosis: systematic DXA or pre-screening with questionnaires? An economic point of view
Richy, Florent; Ethgen, Olivier ULg; Bruyère, Olivier ULg et al

in Osteoporosis International (2005, March), 16(Suppl.3), 101

Detailed reference viewed: 9 (1 ULg)
Full Text
Peer Reviewed
See detailResponders to glucosamine sulfate in knee osteoarthritis
Bruyère, Olivier ULg; Pavelka, K.; Richy, Florent et al

in Osteoporosis International (2005, March), 16(Suppl.3), 77

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailA critical analysis of the efficacy of estrogens on spinal and non-spinal fracture reduction
Reginster, Jean-Yves ULg; Richy, Florent; Bruyère, Olivier ULg

in Osteoporosis International (2005, March), 16(Suppl.3), 47

Detailed reference viewed: 7 (1 ULg)
Full Text
Peer Reviewed
See detailOne-year progression of knee osteoarthritis: correlations between X-Rays and magnetic resonance imaging changes
Bruyère, Olivier ULg; Kothari, M.; Zaim, S. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 46-47

Detailed reference viewed: 13 (7 ULg)
Full Text
Peer Reviewed
See detailFemoro-tibial joint space width, assessed by standard X-Ray, is associated with tibial cartilage volume and thickness, assessed by magnetic resonance imaging
Bruyère, Olivier ULg; Kothari, M.; Zaim, S. et al

in Osteoporosis International (2005, March), 16(Suppl.3), 46

Detailed reference viewed: 14 (1 ULg)
Full Text
Peer Reviewed
See detailAn indirect comparison of the efficacies of vitamin D and its hydroxylated analogs in postmenopausal and corticosteroid-induced osteoporosis
Richy, Florent; Schacht, E.; Bruyère, Olivier ULg et al

in Osteoporosis International (2005, March), 16(Suppl.3), 29

Detailed reference viewed: 5 (2 ULg)